Please ensure Javascript is enabled for purposes of website accessibility

Zoetis Receives FDA Approval for Parasite Prevention Drug for Dogs

By Mark Prvulovic - Feb 27, 2020 at 4:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's the first chewable tablet of its kind to treat heartworm disease, ticks, and fleas.

Zoetis (ZTS 1.44%) announced on Thursday that its new all-in-one parasite protection treatment for dogs had received approval from the U.S. Food and Drug Administration. Simparica Trio is a once-per-month chewable tablet that protects dogs from three prominent types of parasites common to canines, heartworm disease, fleas, and ticks.

Clinical studies testing Simparica Trio demonstrated 100% efficacy in preventing the onset of heartworm disease, as well as a 98.9% effectiveness in fighting existing tick infestations in dogs. Simparica Trio also has a 100% efficacy in killing fleas eight hours after the initial treatment. While the treatment isn't as certain for other types of parasites, tests have shown that it's also reasonably reliable in eliminating roundworms (99% effective) and hookworms (94% effective).

A person holding a red pill in front of a dog.

Image source: Getty Images.

"Simparica Trio makes it easier for dog owners to follow their veterinarians' recommendations for parasite protection because it covers the most common parasites in just one convenient chewable," said Chris Adolph, a senior veterinary specialist at Zoetis.

Further details

Zoetis is the world's largest producer of veterinary medicines and pharmaceutical products for animals. Over the past 18 months, it received a number of additional approvals for parasitic prevention products to help cats and dogs. One of them is a treatment called ProHeart, which was approved on July 19 as a once-per-year injection to prevent heartworm disease in dogs. Before that, Zoetis received approval for Revolution Plus in November 2018, a 6-in-1 topical parasite protection treatment for cats and kittens.

Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zoetis Inc. Stock Quote
Zoetis Inc.
$175.67 (1.44%) $2.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.